The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The website provides information about neuroendocrine cancer and patient stories. It has many other resources and links. The Carcinoid Cancer Foundation is an American organisation that encourages and ...

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. “This FDA approval marks a meaningful ...